Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]asyn-44
- Development stage
- Discontinued
- Lead developer
- Center for Addiction and Mental Health
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[18F]asyn-44 is a fluorine-18 labeled pyridothiophene-based positron emission tomography (PET) radiotracer designed for the in vivo imaging of pathological alpha-synuclein (α-syn) aggregates. Developed by researchers at the Centre for Addiction and Mental Health (CAMH), the University of Pittsburgh, and collaborating institutions, the tracer was intended to aid in the early diagnosis, differential classification, and therapeutic monitoring of synucleinopathies, including Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). Although [18F]asyn-44 demonstrated high binding affinity to α-syn aggregates in vitro and good initial brain uptake in preclinical animal models (including rodents, pigs, and non-human primates), its further clinical translation was halted due to rapid metabolism and the formation of troublesome radiometabolites.
- Other names
- Fluorine-18 asyn-44Fluorine18 asyn-44Fluorine 18 asyn-44
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on [18F]asyn-44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]asyn-44.